The influence of abacavir and other antiretroviral agents on virological response to HCV therapy among antiretroviral-treated HIV-infected patients | Zendy

Valerianna Amorosa | Zendy; Jihad Slim | Zendy; Karam Mounzer | Zendy; Christopher Bruno | Zendy; Margaret Hoffman-Terry | Zendy; Z. Dorey-Stein | Zendy; Thomas Ferrara | Zendy; Jay R. Kostman | Zendy; Vincent Lo Re | Zendy

Open Access

The influence of abacavir and other antiretroviral agents on virological response to HCV therapy among antiretroviral-treated HIV-infected patients

Author(s) -

Valerianna Amorosa,

Jihad Slim,

Karam Mounzer,

Christopher Bruno,

Margaret Hoffman-Terry,

Z. Dorey-Stein,

Thomas Ferrara,

Jay R. Kostman,

Vincent Lo Re

Publication year - 2010

Publication title -

antiviral therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.747

H-Index - 87

eISSN - 2040-2058

pISSN - 1359-6535

DOI - 10.3851/imp1492

Subject(s) - abacavir , medicine , ribavirin , pegylated interferon , viral load , odds ratio , confidence interval , discontinuation , hepatitis c , cohort , virology , hepatitis c virus , immunology , human immunodeficiency virus (hiv) , antiretroviral therapy , virus

It remains unclear if certain antiretroviral medications, particularly abacavir, compromise response to HCV therapy. Such data could inform the selection of appropriate antiretrovirals in HIV/HCV-coinfected patients. The aim of this study was to determine if use of abacavir, as well as other antiretrovirals, was associated with reduced response to pegylated interferon (PEG-IFN) plus ribavirin.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research